Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer

被引：0
|
作者：
Schilsky, R. L.
Geary, D.
Skoog, L.
Desai, A.
Valickas, J.
Masson, E.
Laurent, D.
Pendowski, C.
Vokes, E.
Ratain, M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Novartis Oncol, E Hanover, NJ USA
[3] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3595
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma-Results of a phase I trial
    Brandes, A. A.
    Stupp, R.
    Hau, P.
    Sleijfer, S.
    Lacombe, D.
    Gorlia, T.
    Yun, H.
    Tosoni, A.
    Mirimanoff, R.
    van den Bent, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temazolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
    Reardon, D
    Friedman, H
    Yung, WKA
    Brada, M
    Conrad, C
    Provenzale, J
    Jackson, E
    Serajuddin, H
    Chen, B
    Laurent, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 110S - 110S
  • [43] Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: An animal study
    Schoenberger, J
    Grimm, D
    Kossmehl, P
    Infanger, M
    Kurth, E
    Eilles, C
    ENDOCRINOLOGY, 2004, 145 (03) : 1031 - 1038
  • [44] Synergistic inhibitory effects of PTK787/ZK222584 and interferon-alfa on hepatocellular carcinoma with metastatic potential
    Liu, Yuqing
    Poon, Ronnie Tung-Ping
    Li, Lei
    Qian, Xuemin
    Chen, Yongjun
    Xu, Yang
    Sun, Huichuan
    Tang, Zhaoyou
    Fan, Sheungtat
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A94 - A94
  • [45] A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients
    Pavel, M.
    Schuppan, D.
    Jost, L.
    Kerr, D.
    Harris, A.
    Jalava, T.
    Masson, E.
    Palacay-Radona, M. L. D.
    Koehne, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 427 - 427
  • [46] A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
    Thomas, A. L.
    Trarbach, T.
    Bartel, C.
    Laurent, D.
    Henry, A.
    Poethig, M.
    Wang, J.
    Masson, E.
    Steward, W.
    Vanhoefer, U.
    Wiedenmann, B.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 782 - 788
  • [47] IN VITRO AND IN VIVO STUDIES REVEAL THAT THE VEGF-R INHIBITOR PTK787/ZK222584 IS A COMPETITIVE AROMATASE INHIBITOR
    Banerjee, S. N.
    Zvelebil, M.
    Furet, P.
    Mueller-Vieira, U.
    Dowsett, M.
    Evans, D.
    Martin, L.
    ANNALS OF ONCOLOGY, 2009, 20 : 61 - 61
  • [48] Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
    Joensuu, H.
    De Braud, F.
    Coco, P.
    De Pas, T.
    Putzu, C.
    Spreafico, C.
    Bono, P.
    Bosselli, S.
    Jalava, T.
    Laurent, D.
    Casali, P. G.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 173 - 177
  • [49] A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
    Jeffrey J. Raizer
    Sean A. Grimm
    Alfred Rademaker
    James P. Chandler
    Kenji Muro
    Irene Helenowski
    Laurie Rice
    Katie McCarthy
    Sandra K. Johnston
    Maciej M. Mrugala
    Marc Chamberlain
    Journal of Neuro-Oncology, 2014, 117 : 93 - 101
  • [50] A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
    Raizer, Jeffrey J.
    Grimm, Sean A.
    Rademaker, Alfred
    Chandler, James P.
    Muro, Kenji
    Helenowski, Irene
    Rice, Laurie
    McCarthy, Katie
    Johnston, Sandra K.
    Mrugala, Maciej M.
    Chamberlain, Marc
    JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (01) : 93 - 101
12345